High dose cytosine arabinoside in the management of refractory acute leukaemia.
High dose cytosine arabinoside in the management of refractory acute leukaemia.
复制标题
高剂量阿糖胞苷治疗难治性急性白血病。
DOI：
10.1111/j.1600-0609.1982.tb00575.x
复制
发表时间：
2009
期刊：
影响因子：
--
通讯作者：
J. Keuning
中科院分区：
文献类型：
--
作者：
R. Willemze;F. Zwaan;G. Colpin;J. Keuning
用大剂量阿糖胞苷（AraC）治疗难治性急性白血病17例（年龄15-58岁）（AML 14例，ALL 3例），剂量3000 mg/m2，每日2次，疗程6d。9例患者完全缓解（53%），2例部分缓解。虽然在全血细胞减少期间需要复杂的隔离和血库设施，但这种治疗的毒性是可以接受的。呕吐、头痛、嗜睡、发热、结膜炎和心律失常最常见。3例患者发生非预期肺功能衰竭，令人担忧。缓解时间为1 ~ 12个月。使用高剂量AraC获得的结果是令人满意的，并且有望用于治疗先前未经治疗的AML患者。
17 patients (age 15-58 years) with refractory acute leukaemia (14 AML, 3 ALL) were treated with high dose cytosine arabinoside (AraC) at a dose of 3000 mg/m2, twice daily for 6 d (13 patients with AraC alone, 4 patients with AraC and doxorubicin). 9 patients achieved complete remission (53%) and 2 a partial remission. Although sophisticated isolation and blood banking facilities are required during the pancytopenic period, the toxicity of this treatment was acceptable. Vomiting, headache, somnolence, fever, conjunctivitis and cardiac arrhythmias were found most frequently. The unexpected pulmonary failure in 3 patients was worrisome. The duration of remissions was from 1 to 12 months. Results obtained with high dose AraC are satisfactory and hold promise for the treatment of patients with previously untreated AML.